Skip to main content
SpringerLink
Log in

Targeted Breast Cancer Therapy

  • Chapter
  • First Online:
Personalized Medicine in Healthcare Systems

Part of the book series: Europeanization and Globalization ((EAG,volume 5))

  • 662 Accesses

Abstract

Despite great advances in treatment, breast cancer is still the most common cause of death in cancer-treated women. From the results of numerous clinical studies and meta-analyses, the development of chemotherapy in the treatment of breast cancer has brought significant clinical benefit to survival, whether the treatment is adjuvant or the one of metastatic disease. The development of core oncology, translational and clinical research has led to a better understanding of the biology and immunology of tumors, the generation of new immunotherapeutic possibilities and their implementation in everyday clinical practice. For now, mostly monoclonal antibodies, primarily trastuzumab, are used in clinical practice, which is the gold standard for the treatment of HER-2 positive patients. Besides lapatinib, further development of this area has resulted in introducing pertuzumab, a monoclonal antibody directed against the second binding site of the HER-2 receptor, and trastuzumab-DM1, a true pathway for further development of immunotherapy, a cytostatic and antibody conjugate. Phase III clinical trials have confirmed the efficacy of pertuzumab and trastuzumab-DM1. The other direction the development of tumor immune therapy was based on was focusing on the infrastructure of the host, especially the blood vessels. For this purpose, a monoclonal antibody directed against the vascular endothelial growth factor (VEGF), bevacizumab, has been developed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Slamon et al. (2001).

  2. 2.

    Slamon et al. (2009).

  3. 3.

    Perez et al. (2007).

  4. 4.

    Perez et al. (2009).

  5. 5.

    Piccart-Gebhart et al. (2005).

  6. 6.

    Joensuu et al. (2009).

  7. 7.

    Spielmann et al. (2009).

  8. 8.

    Slamon et al. (2009).

  9. 9.

    Perez et al. (2007).

  10. 10.

    Perez et al. (2009).

  11. 11.

    Cobleigh et al. (1999); Baselga and Swan (2009); Vogel et al. (2002).

  12. 12.

    Piccart-Gebhart et al. (2005).

  13. 13.

    Marty et al. (2005).

  14. 14.

    Robert et al. (2006).

  15. 15.

    Forbes et al. (2006).

  16. 16.

    Láng et al. (2014).

  17. 17.

    von Minckwitz et al. (2009).

  18. 18.

    Baselga and Swan (2009).

  19. 19.

    Blackwell et al. (2009).

  20. 20.

    Untch et al. (2010).

  21. 21.

    Gianni et al. (2010).

  22. 22.

    Di Cosimo and Baselga (2008).

  23. 23.

    Geyer et al. (2006).

  24. 24.

    Baselga et al. (2012a).

  25. 25.

    Baselga et al. (2012b).

  26. 26.

    Cortes et al. (2013).

  27. 27.

    Swain et al. (2013a).

  28. 28.

    Swain et al. (2013b).

  29. 29.

    Kimberly et al. (2012).

  30. 30.

    Dieras et al. (2017).

  31. 31.

    Schneider and Sledge (2011).

  32. 32.

    Miles et al. (2010).

  33. 33.

    Robert et al. (2011).

  34. 34.

    Brufsky et al. (2011).

  35. 35.

    Gianni et al. (2013).

References

  • Baselga J, Swan MS (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Canc 9(7):463–475. https://doi.org/10.1038/nrc2656

    Article  Google Scholar 

  • Baselga J, Bradbury I, Eidtmann H et al (2012a) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial. Lancet 379(9816):633–640. https://doi.org/10.1016/S0140-6736(11)61847-3

    Article  Google Scholar 

  • Baselga J, Cortes J, Kim SB et al (2012b) Pertuzumab plus trastuzumab docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119. https://doi.org/10.1056/NEJMoa1113216

    Article  Google Scholar 

  • Blackwell KL, Burstein HJ, Sledge GW (2009) Updated survival analysis of a randomized study of Lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 69(24 Suppl 3):Abstract 61. https://doi.org/10.1158/0008-5472.SABCS-09-61

  • Brufsky AM, Hurvitz S, Perez E et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy, for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32):4286–4293. https://doi.org/10.1200/JCO.2010.34.1255

    Article  Google Scholar 

  • Cobleigh MA, Vogel C, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648. https://doi.org/10.1200/jco.1999.17.9.2639

    Article  Google Scholar 

  • Cortes J, Baselga J, Im YH et al (2013) Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 24(10):2630–2635. https://doi.org/10.1093/annonc/mdt274

    Article  Google Scholar 

  • Di Cosimo S, Baselga J (2008) Targeted therapy in breast cancer: where are we now? Eur J Cancer 44(18):2781–2790. https://doi.org/10.1016/j.ejca.2008.09.026

    Article  Google Scholar 

  • Dieras V, Miles D, Verma S et al (2017) Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18(6):732–742. https://doi.org/10.1016/S1470-2045(17)30312-1

    Article  Google Scholar 

  • Forbes JF, Kennedy J, Pienkowski T et al (2006) BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer(MBC): main time to progression (TTP) analysis J Clin Oncol 24(Suppl 18):A-LBA516, 7s

    Google Scholar 

  • Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. https://doi.org/10.1056/NEJMoa064320

    Article  Google Scholar 

  • Gianni L, Eirmann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial). Lancet 375(9712):377–384

    Article  Google Scholar 

  • Gianni L, Romieu GH, Lichinitser M et al (2013) AVEREL: a randomized phase III trial evaluating Bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31(14):1719–1725. https://doi.org/10.1200/JCO.2012.44.7912

    Article  Google Scholar 

  • Joensuu H, Bono P, Kataja V et al (2009) Fluorouracil, epirubucun, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27(34):5685–5692

    Article  Google Scholar 

  • Kimberly L, Blackwell K, Miles D et al (2012) Primary results from EMILIA, a phase 3study of trastuzumab-emtansine (T-DM-1) vs capecitabine (X) and lapatinib (L) in HER2 positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 30:18_suppl,LBA-LBA1. https://doi.org/10.1200/jco.2012.30.18_suppl.lba1

    Article  Google Scholar 

  • Láng I, Bell R, Feng FY, Lopez RI et al (2014) Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the retreatment after herceptin adjuvant trial. Clin Oncol (R Coll Radiol) 26(2):81–89. https://doi.org/10.1016/j.clon.2013.08.011

    Article  Google Scholar 

  • Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive breast cancer administreted as firstline treatment: the M77001 study group. J Clin Oncol 23(19):4265–4274

    Article  Google Scholar 

  • Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239–3247. https://doi.org/10.1200/JCO.2008.21.6457

    Article  Google Scholar 

  • Perez E, Suman V, Davidson N et al (2009) Results of chemotherapy alone with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2 positive adjuvant breast cancer trial. In: Program and abstracts of the 32nd Annual San Antonio Breast Cancer Symposium; December 9–13, San Antonio, Texas, Abstract 80

    Google Scholar 

  • Perez EA, Romond EH, Suman VJ et al (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/witouth trastuzumab in patients with HER-2 breast cancer (abstract). J Clin Oncol 25(18):Abstract 512. https://doi.org/10.1200/jco.2007.25.18_suppl.512

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672

    Article  Google Scholar 

  • Robert N, Leyland-Jones B, Asmar L et al (2006) Randomised phase III study of trastuzumab, paclitaksel, and carboplatin compared with trastuzumab and palitaksel in women with HER-2 overexpressing metastatis breast cancer. J Clin Oncol 24(18):2786–2792

    Article  Google Scholar 

  • Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252–1260. https://doi.org/10.1200/JCO.2010.28.0982

    Article  Google Scholar 

  • Schneider BP, Sledge GW Jr (2011) Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? J Clin Oncol 29(18):2444–2447. https://doi.org/10.1200/JCO.2011.34.9266

    Article  Google Scholar 

  • Slamon D, Eiermann W, Robert N et al (2009) Phase III trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: BCIRG 006 study. In: Third Planned Efficacy Analysis. Program and abstracts of the 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, San Antonio, Texas, Abstract 62

    Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 344(11):783–792

    Article  Google Scholar 

  • Spielmann M, Roche H, Delozier T et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134

    Article  Google Scholar 

  • Swain SM, Ewer MS, Cortes J et al (2013a) Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 18(3):257–264. https://doi.org/10.1634/theoncologist.2012-0448

    Article  Google Scholar 

  • Swain SM, Sung-Bae K, Cortes J et al (2013b) Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study. Lancet Oncol 14(6):461–471. https://doi.org/10.1016/S1470-2045(13)70130-X

    Article  Google Scholar 

  • Untch M, Rezai M, Loibl S et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQUattro study. J Clin Oncol 28(12):2024–2031

    Article  Google Scholar 

  • Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumag as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726. https://doi.org/10.1200/JCO.2002.20.3.719

    Article  Google Scholar 

  • von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27(12):1999–2006. https://doi.org/10.1200/JCO.2008.19.6618

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Radiotherapy and Oncology, University Hospital Center Rijeka, Rijeka, Croatia

    Ingrid Belac Lovasić & Franjo Lovasić

Authors
  1. Ingrid Belac Lovasić
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franjo Lovasić
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Law, University of Rijeka, Rijeka, Croatia

    Nada Bodiroga-Vukobrat

  2. Croatian Academy of Sciences and Arts, Rijeka, Croatia

    Daniel Rukavina

  3. Juraj Dobrila University of Pula, Faculty of Medicine, Pula, Croatia

    Krešimir Pavelić

  4. Department of Biotechnology, Centre for High-Throughput Technologies, University of Rijeka, Rijeka, Croatia

    Krešimir Pavelić

  5. University of Applied Sciences, Ludwigsburg, Germany

    Gerald G. Sander

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Belac Lovasić, I., Lovasić, F. (2019). Targeted Breast Cancer Therapy. In: Bodiroga-Vukobrat, N., Rukavina, D., Pavelić, K., Sander, G.G. (eds) Personalized Medicine in Healthcare Systems. Europeanization and Globalization, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-030-16465-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16465-2_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16464-5

  • Online ISBN: 978-3-030-16465-2

  • eBook Packages: Law and CriminologyLaw and Criminology (R0)

Publish with us

Policies and ethics

Search

Navigation